| • Known or suspected hypersensitivity to trial product(s) or related products |
| • For female patients, pregnancy, breast-feeding, or the potential to become pregnant (specific criteria varied in some countries). Males of reproductive age were excluded if they or their partner(s) were not using adequate contraceptive methods |
| • Active malignant disease or history of malignancy, with some exceptions |
| • History of pituitary adenomas or other benign intracranial tumors, unless the tumor had been surgically removed >12 months before randomization or the patients had stable and clinically non-functioning adenomas for ≥3 years, with the most recent scan within 9 months prior to randomization |
| • Clinically significant renal or hepatic disease |
| • A history of positive tests for hepatitis B and/or C or for human immunodeficiency virus antibodies |
| • Acute severe illness associated with weight loss <180 days prior to randomization |
| • Active Cushing’s syndrome <24 months prior to randomization |
| • Heart insufficiency (NYHA class >2) |
| • A history of acromegaly |
| • Use of systemic corticosteroids other than in replacement doses within 90 days before randomization |
| • Mental incapacity/language barriers which precluded adequate participation |
| • Known or suspected hypersensitivity to trial product(s) or related products |
| • For female patients, pregnancy, breast-feeding, or the potential to become pregnant (specific criteria varied in some countries). Males of reproductive age were excluded if they or their partner(s) were not using adequate contraceptive methods |
| • Active malignant disease or history of malignancy, with some exceptions |
| • History of pituitary adenomas or other benign intracranial tumors, unless the tumor had been surgically removed >12 months before randomization or the patients had stable and clinically non-functioning adenomas for ≥3 years, with the most recent scan within 9 months prior to randomization |
| • Clinically significant renal or hepatic disease |
| • A history of positive tests for hepatitis B and/or C or for human immunodeficiency virus antibodies |
| • Acute severe illness associated with weight loss <180 days prior to randomization |
| • Active Cushing’s syndrome <24 months prior to randomization |
| • Heart insufficiency (NYHA class >2) |
| • A history of acromegaly |
| • Use of systemic corticosteroids other than in replacement doses within 90 days before randomization |
| • Mental incapacity/language barriers which precluded adequate participation |
| • Known or suspected hypersensitivity to trial product(s) or related products |
| • For female patients, pregnancy, breast-feeding, or the potential to become pregnant (specific criteria varied in some countries). Males of reproductive age were excluded if they or their partner(s) were not using adequate contraceptive methods |
| • Active malignant disease or history of malignancy, with some exceptions |
| • History of pituitary adenomas or other benign intracranial tumors, unless the tumor had been surgically removed >12 months before randomization or the patients had stable and clinically non-functioning adenomas for ≥3 years, with the most recent scan within 9 months prior to randomization |
| • Clinically significant renal or hepatic disease |
| • A history of positive tests for hepatitis B and/or C or for human immunodeficiency virus antibodies |
| • Acute severe illness associated with weight loss <180 days prior to randomization |
| • Active Cushing’s syndrome <24 months prior to randomization |
| • Heart insufficiency (NYHA class >2) |
| • A history of acromegaly |
| • Use of systemic corticosteroids other than in replacement doses within 90 days before randomization |
| • Mental incapacity/language barriers which precluded adequate participation |
| • Known or suspected hypersensitivity to trial product(s) or related products |
| • For female patients, pregnancy, breast-feeding, or the potential to become pregnant (specific criteria varied in some countries). Males of reproductive age were excluded if they or their partner(s) were not using adequate contraceptive methods |
| • Active malignant disease or history of malignancy, with some exceptions |
| • History of pituitary adenomas or other benign intracranial tumors, unless the tumor had been surgically removed >12 months before randomization or the patients had stable and clinically non-functioning adenomas for ≥3 years, with the most recent scan within 9 months prior to randomization |
| • Clinically significant renal or hepatic disease |
| • A history of positive tests for hepatitis B and/or C or for human immunodeficiency virus antibodies |
| • Acute severe illness associated with weight loss <180 days prior to randomization |
| • Active Cushing’s syndrome <24 months prior to randomization |
| • Heart insufficiency (NYHA class >2) |
| • A history of acromegaly |
| • Use of systemic corticosteroids other than in replacement doses within 90 days before randomization |
| • Mental incapacity/language barriers which precluded adequate participation |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
